UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

~~PURSUANT~~Pursuant TOto ~~SECTION~~Section 13 ORor 15(d) ~~OF THE~~

~~SECURITIES~~of ~~EXCHANGE~~the ~~ACT~~Securities OFExchange Act of 1934

Date of Report (Date of earliest event reported): ~~April~~May 1018, 2026

EVOFEM BIOSCIENCES, INC.

(Exact name of registrant as specified in its charter)

Delaware	001-36754	20-8527075
(State or other jurisdiction	(Commission	(I.R.S. Employer
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)
of incorporation)	File Number)	Identification No.)

7770 Regents Road, Suite 113-618

San Diego, ~~California~~CA 92122

(Address of ~~principal~~Principal ~~executive~~Executive ~~offices~~Offices)

(858) 550-1900

(Registrant’s telephone number, including area code)

~~N/A~~Not applicable.

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the ~~Registrant~~registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading Symbol(s) Name of each exchange on which registered None

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). ~~Emerging Growth Company ☐~~

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 12.0102. ~~Entry~~Results ~~into~~of aOperations ~~Material~~and ~~Definitive~~Financial ~~Agreement~~Condition.

~~Amendment~~On May 18, 2026, Evofem Biosciences, Inc. (the “Company”) issued a press release announcing its financial results for the three months ended March 31, 2026. A copy of the press release is furnished as Exhibit 99.1 to ~~Securities~~this ~~Purchase~~Current ~~Agreement~~Report on Form 8-K.

OnThe ~~April~~information ~~10,~~set ~~2026~~forth ~~(the~~in ~~“Effective~~this ~~Date”),~~item ~~Evofem~~2.02 ~~Biosciences,~~and ~~Inc~~in Exhibit 99.1 ~~(the~~is ~~“Company”),~~not ~~Adjuvant~~being ~~Global~~filed ~~Health~~for ~~Technology Fund,~~purposes ~~L.P.,~~of ~~and~~Section ~~Adjuvant~~18 ~~Global~~of ~~Health~~the ~~Technology~~Securities ~~Fund~~Exchange Act ~~DE,~~of ~~L.P.~~1934 ~~(together,~~and ~~“Adjuvant”)~~is ~~entered~~not to be incorporated by reference into aany ~~fourth~~filing ~~amendment~~of (the ~~“Fourth~~ ~~Amendment”)~~registrant tounder the Securities ~~Purchase~~Act ~~Agreement~~of ~~dated~~1933 asor ofthe ~~October~~Securities Exchange ~~14,~~Act ~~2020~~of 1934, aswhether ~~amended~~made before or after the date hereof, ~~pursuant~~regardless toof ~~which~~any general incorporation language in any such filing, ~~Adjuvant~~except ~~purchased~~as ~~from~~shall ~~the~~be ~~Company~~expressly ~~certain~~set ~~convertible~~forth ~~promissory~~by ~~notes~~specific ~~(the~~reference ~~“Notes”)~~in such a filing.

~~The~~Forward-Looking Fourth Amendment amends certain provisions within the Securities Purchase Agreement including updating the date that the Notes will be payable in full to the earlier of (a) six months after the Effective Date, (b) at the election of Adjuvant, the date of a consummation of a Change of Control (as defined in the Securities Purchase Agreement), and (c) the date of any acceleration of the Notes in accordance with Section 8 (the “Maturity Date”, as per the Securities Purchase Agreement). The Notes may not be prepaid prior to the date that is six months after the Effective Date without prior written consent of Adjuvant.Statements

The press release incorporated into this Current Report on Form 8-K includes “forward-looking statements,” within the meaning of the safe harbor for forward-looking statements provided by Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Words such as, but not limited to, “anticipate,” “aim,” “believe,” “contemplate,” “continue,” “could,” “design,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “seek,” “should,” “suggest,” “strategy,” “target,” “will,” “would,” and similar expressions or phrases, or the negative of those expressions or phrases, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These statements include but are not limited to Evofem’s expectations regarding the anticipated impact of COGS reduction initiatives, future sales trends, cost-reduction initiatives, manufacturing efficiencies, international market expansion, and the Company’s ability to obtain additional financing or other strategic alternatives. Forward-looking statements are based on current assumptions and involve known and unknown risks and uncertainties, many of which are beyond the Company’s control. Important factors that could cause actual results to differ materially from those discussed or implied in the forward-looking statements include, but are not limited to, limited cash resources, dependence on new capital or business development transactions to fund operations, potential delays in regulatory approvals, changes in market demand, manufacturing and supply chain risks, the nonrecurring nature of certain recent gains, together with those that are disclosed in the Company’s SEC filings, including its Annual Report on Form 10-K for the year ended December 31, 2025 filed with the SEC on March 11, 2026 and any subsequent filings. All forward-looking statements are expressly qualified in their entirety by such factors. Evofem undertakes no obligation to update or revise any forward-looking statement except as required by law, and investors are cautioned not to place undue reliance on such statements given the Company’s current liquidity position and evolving business conditions.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
10.1		Fourth Amendment to Securities Purchase Agreement dated as of April 10, 2026
99.1		Press Release dated May 18, 2026
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	EVOFEM BIOSCIENCES, INC.
Dated: April 16, 2026	By:	/s/ Saundra Pelletier
Date: May 18, 2026	By:	/s/ Ivy Zhang
		Saundra Pelletier
		Ivy Zhang
		Chief Executive Officer
		Chief Financial Officer

Filing Compare · Evofem Biosciences, Inc.